Archive: News
-
Treatment with solanezumab is not effective in preventing Alzheimer’s disease
Katie Seidenberg and R. Scott Turner Eli Lilly and collaborators released the topline results of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study March 8th (NCT02008357 on
Category: News
-
Lecanumab (LeqembiTM) FDA-approved for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD) – collectively called early AD R. Scott Turner
R. Scott Turner A breakthrough, finally! Leqembi is the first disease-modifying treatment for individuals with MCI and mild AD with solid evidence of effectiveness. Thus, Leqembi (previously calle
Category: News
-
MDP in the News
The Memory Disorders Program's own Clinical Trial Manager, Angelica Forero, was interviewed about a groundbreaking clinical trial at Georgetown using 'nicotine' to end memory loss. See the full artic
Category: News
-
Allegations of fraud in Alzheimer’s disease research- death of the amyloid hypothesis?
R. Scott Turner, PhD, MD Recent reports of fraud in Alzheimer’s disease (AD) research have raised major concerns. Some of the figures in a highly-cited paper (using animal models of AD) published
Category: News
-
These Simple Tasks Can Cut Your Risk Of Dementia, Study Finds
29 JULY 2022: Link to Huffington Post article
Category: News
-
Achieving Greater Diversity in Dementia Research: A Call to Action
by R. Scott Turner and Charlyn Gomez: In the US, individuals in URGs are defined as Black or African-American, Hispanic/Latinx, Indigenous and Native American, Asian, Native Hawaiians and other P
Category: News
-
Nicotine to Help Treat Memory Loss?
**Reference pg. A6 for article: A study funded by the National Institutes of health is testing whether the nicotine patch can improve memory and functioning in people who have mild memory loss or
Category: News
-
Memory Disorders Program Intern and First SCS Student Wins Lena Landegger Community Service Award
For the first time, an SCS student has won Georgetown’s Lena Landegger Community Service award: James Jaramillo, a graduate of the Bachelor of Arts in Liberal Studies Program A graduate of the Cla
Category: News
-
New Developments in Alzheimer’s Disease Therapeutics
R. Scott Turner, PhD, MD Memory Disorders Program, MedStar Georgetown University Hospital Nov. 18, 2021 Aducanumab (Aduhelm®) On June 7, 2021 the FDA granted accelerated approval of the anti
Categories: Aducanumab, New developments, News
-
Alzheimer’s Association On Demand Webinars
View some free, on demand webinars regarding a variety of Alzheimer's topics including Aducanmunab on the Alzheimer's Association website. View Here https://www.alz.org/research/for_researcher
Categories: Aducanumab, Events, News